DII
SRPT icon

Domini Impact Investments’s Sarepta Therapeutics SRPT Stock Holding History

Domini Impact Investments’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6,872
Closed -$265K – 14
2015
Q4 		$265K Sell
6,872
-1,792
-21% -$58.1K 5.16% 9
2015
Q3 		$278K Buy
8,664
+1,068
+14% +$36.2K 4.54% 11
2015
Q2 		$231K Buy
+7,596
New +$155K 3.56% 16

Other funds holding SRPT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Domini Impact Investments's SRPT Position: Q1 2016 in Review

Domini Impact Investments sold out of Sarepta Therapeutics (SRPT) in Q1 2016, closing a stake of 6,872 shares — an estimated $265K sold.

Domini Impact Investments first reported a position in SRPT in Q2 2015 and held it in 3 quarters. The position peaked at $278K in Q3 2015. 132 funds tracked by Wall St. Rank hold SRPT as of Q1 2016.

  • Domini Impact Investments reported no remaining Sarepta Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Domini Impact Investments sold 6,872 Sarepta Therapeutics shares in Q1 2016, an estimated $265K.
  • Domini Impact Investments first reported a position in Sarepta Therapeutics in Q2 2015 and held it in 3 quarters.
  • Domini Impact Investments's Sarepta Therapeutics position peaked at $278K in Q3 2015.
  • 132 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2016.

Based on Domini Impact Investments's 13F filing for Q1 2016, filed 12 May 2016.